Odense, Denmark

Jens Christian Jensenius

USPTO Granted Patents = 8 


Average Co-Inventor Count = 1.7

ph-index = 6

Forward Citations = 141(Granted Patents)


Location History:

  • Odense, DK (1990)
  • 5230 Odense M, DK (1994)
  • Odense M, DK (1992 - 2006)
  • DK-5230 Odense, DK (2003 - 2008)

Company Filing History:


Years Active: 1990-2008

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Innovations by Jens Christian Jensenius

Introduction

Jens Christian Jensenius is a notable inventor based in Odense, Denmark. He has made significant contributions to the field of immunology, particularly through his innovative patents. With a total of eight patents to his name, Jensenius has focused on developing treatments for immunocompromised individuals.

Latest Patents

One of Jensenius's latest patents involves the use of mannan-binding lectin (MBL) in the treatment of infections in immunocompromised individuals. This invention relates to a composition that includes at least one MBL subunit or oligomer, which can be manufactured into a medicament for prophylaxis and treatment of infections. The invention is particularly relevant for individuals suffering from neutropenia, especially those undergoing chemotherapy or similar treatments. It has been shown that individuals with serum MBL levels ranging from 50 ng/ml to 500 ng/ml can benefit from this treatment, regardless of their serum MBL levels.

Career Highlights

Throughout his career, Jensenius has worked with prominent companies, including Novo Nordisk A/S. His work has significantly impacted the development of medical treatments aimed at improving the health of immunocompromised patients.

Collaborations

Jensenius has collaborated with notable colleagues such as Steffen Thiel and Thomas Vorup Jensen. Their combined expertise has contributed to the advancement of research in immunology and treatment methodologies.

Conclusion

Jens Christian Jensenius is a distinguished inventor whose work in immunology has led to innovative treatments for immunocompromised individuals. His contributions continue to influence the medical field and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…